GRTX — Galera Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $10.12m
- $142.91m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -51.9 | -74.2 | -80.5 | -62.2 | -59.1 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 5.67 | 10.4 | 14.4 | 15.5 | 20.1 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.655 | 3.91 | -2.63 | 3.26 | -6.17 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -46.7 | -59.5 | -68 | -43.4 | -44.8 |
Capital Expenditures | -0.633 | -0.457 | -0.283 | -0.025 | -0.059 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -27.2 | 37 | 5.52 | 24 | 27.4 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -27.8 | 36.5 | 5.24 | 24 | 27.3 |
Financing Cash Flow Items | 0 | — | — | — | 2.01 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 78 | 20.5 | 66.7 | 3.89 | 31.5 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 3.54 | -2.48 | 3.99 | -15.5 | 13.9 |